Excellent prenatal alloimmunization/HDFN care practices

The following constitutes a list of management, intervention and support practices which reflect the available peer-reviewed literature and expert opinion for the management of maternal red blood cell alloimmunization causing hemolytic disease of the fetus and newborn (HDFN). This list is meant to serve as a resource as patients are selecting a care provider, and as a criterion which members of the Allo Hope Foundation (AHF) use to recommend doctors among our patient base.

Updated April 2025

Diagnosis and monitoring

- Offers paternal testing and cffDNA testing to avoid amniocentesis for fetal antigen determination if possible.
    - Offers antigen phenotype (or genotype for RhD) testing for baby's father when possible
    - Facilitates cffDNA testing to patients with D, K, C, c, E and Duffy (Fya) antibodies when fetal antigen status is unknown. cffDNA NIPT testing is currently available in the U.S through BilliontoOne (Unity Screen) (100% sensitivity/specificity, 99.9% precision),[1,2] Sanquin Laboratories in the Netherlands (can ship internationally), and through AU, UK, Canadian national laboratories.
    - For fetal antigens not available for testing through cffDNA, amniocentesis after 15 weeks in patients with critical titers and unknown fetal antigen status may be indicated. In these cases, the placenta is avoided at time of amniocentesis to prevent further alloimmunization[3,4]
- Offers temporizing treatment options such as IVIG +/- plasmapheresis to patients with previous severely affected pregnancies (history of IUFD due to HDFN or IUT <24w gestation) or extremely high titers (≥512 for D; ≥64 for K)[5,6]
- Checks antibody titers every 4 weeks until 24 weeks, then every 2 weeks thereafter or if titers are rising, until titers reach critical value[4,7]
- Weekly MCA Doppler scans for women with critical titers beginning at 16 weeks gestation or when titers become critical (critical titer is 4 for Kell, 16 for all other clinically significant antibodies; 4 IU/ml for anti-D in UK)[8]
- Receptive to starting MCA Doppler scans as early as 15 weeks for women with previously affected pregnancies or high titers or referral to a center with experience in doing so[9]
- MCA Doppler Peak Systolic Velocity (PSV) value in multiples of the median (MoM) nearing 1.5 results in prompt re-scan within 24-48hrs, followed by cordocentesis and IUT if levels remain or exceed 1.5 MoM[10]
- Avoids modifying clinical decision to conduct IUT if antenatal corticosteroids were administered in the last 48-72hrs due to its propensity to lower MCA MoM values[11,12]
- Institutes antenatal testing (non-stress test or biophysical profile) at least weekly from 32 weeks gestation until delivery in all alloimmunized pregnancies[13]

Intervention

Note that a clinician without extensive history in performing an IUT may still be an excellent provider for an alloimmunized patient and should remain highly recommended, given that they facilitate prompt referral to a more experienced center for IUTs should the need arise.

If the clinician does perform IUTs, such a clinician:

- Performs IUT promptly after a MoM of 1.5 or higher after confirming anemia via cordocentesis, independent of the presence of hydrops[14]
- Has demonstrated competence in performing IUTs (previous research and Delphi expert consensus has indicated that initial competence is reached at 30-50 IUTs total and an average of 10 IUTs annually[15,16] or is supervised during procedure by an MFM who meets the aforementioned criteria for competence)
- Performs IUTs in an operating room or in a delivery room with immediate access to operating room (a joint decision with the patient)[17]
- Uses fetal paralytic medication during IUTs as indicated[17]
- Offers IV sedative to mother during IUTs[18]
- Does not bring starting hemoglobin/hematocrit up by more than three times the starting value during IUTs in patients < 24 weeks gestation.[18] In these cases, clinician repeats IUT in 48 – 72 hours to achieve normal fetal hematocrit
- Offers follow-up ultrasound the day after IUT[17,18]
- Once IUTs begin, they are continued at reasonable intervals with final IUT at approximately 35 weeks gestation[17,18]

Delivery and postpartum

- Delivers by 37-38 weeks in all alloimmunized pregnancies where the fetus is known to or may have antigen in question independent of antibody titer[7,19]
- Provides patients with a quick and accessible way to communicate with their care team during their pregnancy
- Has a method of ensuring appropriate follow-up care for newborn after birth; this may entail, for example, referral to pediatric hematology before discharge or sending printed instructions for the mother to deliver to their pediatrician

The Allo Hope Foundation provides this checklist as a resource to patients and as a transparent criterion by which AHF staff, board members and volunteers use to determine whether to recommend a clinician to a nearby patient. The Allo Hope Foundation and its staff, board members and volunteers are never incentivized financially or by any other means to recommend a clinician. AHF is not liable for any outcomes that result from the recommendation of a specific clinician.

[1] Gandhi M. Paternal and Fetal Genotyping in the Management of Alloimmunization in Pregnancy. ACOG Clinical Practice Update: Paternal and Fetal Genotyping in the Management of Alloimmunization in Pregnancy. Obstetrics & Gynecology 144(2):p e47-e49, August 2024.
[2] Moise Jr KJ. The use of free DNA for fetal RHD genotyping in the Rh negative pregnant patient—the time has come. American Journal of Obstetrics and Gynecology. 2025 Feb 1;232(2):188-93.
[3]Alford B, Landry BP, Hou S, Bower X, Bueno AM, Chen D, Husic B, Cantonwine DE, McElrath TF, Carozza J, Wynn J. Validation of a Non-invasive Prenatal Test for Fetal RhD, C, c, E, Kell and FyA Antigens. medRxiv. 2023 Mar 20:2023-03.
[4] Royal College of Obstetricians & Gynaecologists. The Management of Women with Red Cell Antibodies during Pregnancy. Green-top Guideline No. 65. May 2014.
[5] Ruma MS, Moise Jr KJ, Kim E, Murtha AP, Prutsman WJ, Hassan SS, Lubarsky SL. Combined plasmapheresis and intravenous immune globulin for the treatment of severe maternal red cell alloimmunization. American journal of obstetrics and gynecology. 2007 Feb 1;196(2):138-e1.
[6] Mustafa HJ, Sambatur EV, Shamshirsaz AA, Johnson S, Moise Jr KJ, Baschat AA, Verweij EJ, Javinani A, Kilby MD, Lopriore E, Rose R. Monitoring and management of hemolytic disease of the fetus and newborn based on an international expert Delphi consensus. American journal of obstetrics and gynecology. 2025 Mar 1;232(3):280-300.
[7] Moise Jr KJ, Abels EA. Management of red cell alloimmunization in pregnancy. Obstetrics & Gynecology. 2022 May 5:10-97.
[8] Zimmermann R, Durig P, Carpenter Jr RJ, Mari G. Longitudinal measurement of peak systolic velocity in the fetal middle cerebral artery for monitoring pregnancies complicated by red cell alloimmunisation: a prospective multicentre trial with intention-to-treat. BJOG: an international journal of obstetrics and gynaecology. 2002 Jul 1;109(7):746-52.
[9] Mari G, Adrignolo A, Abuhamad AZ, Pirhonen J, Jones DC, Ludomirsky A, Copel JA. Diagnosis of fetal anemia with Doppler ultrasound in the pregnancy complicated by maternal blood group immunization. Ultrasound in Obstetrics and Gynecology: The Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology. 1995 Jun 1;5(6):400-5.
[10] Zwiers C, Lindenburg IT, Klumper FJ, De Haas M, Oepkes D, Van Kamp IL. Complications of intrauterine intravascular blood transfusion: lessons learned after 1678 procedures. Ultrasound in Obstetrics & Gynecology. 2017 Aug;50(2):180-6.
[11] Chitrit Y, Caubel P, Herrero R, Schwinte AL, Guillaumin D, Boulanger MC. Effects of maternal dexamethasone administration on fetal Doppler flow velocity waveforms. BJOG. 2000;107(4):501-507.
[12] Urban R, Lemancewicz A, Przepieść J, Urban J, Kretowska M. Antenatal corticosteroid therapy: a comparative study of dexamethasone and betamethasone effects on fetal Doppler flow velocity waveforms. Eur J Obstet Gynecol Reprod Biol. 2005;120(2):170-174.
[13] Moise Jr KJ. Management of rhesus alloimmunization in pregnancy. Obstetrics & Gynecology. 2008 Jul 1;112(1):164-76.
[14] Klumper FJ, van Kamp IL, Vandenbussche FP, Meerman RH, Oepkes D, Scherjon SA, Eilers PH, Kanhai HH. Benefits and risks of fetal red-cell transfusion after 32 weeks gestation. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2000 Sep 1;92(1):91-6.
[15] Lindenburg IT, Wolterbeek R, Oepkes D, Klumper FJ, Vandenbussche FP, Van Kamp IL. Quality control for intravascular intrauterine transfusion using cumulative sum (CUSUM) analysis for the monitoring of individual performance. Fetal diagnosis and therapy. 2011;29(4):307-14.
[16] Moise E, Moise KJ, Nwokocha M, Lowry K, Hutson E, de Winter DP, Delphi IUT Study Group, Antolin E, Audibert F, Baschat AA, Bebbington M. Critical procedural steps in intrauterine transfusion: Delphi survey of international experts. Ultrasound in Obstetrics & Gynecology. 2025 Jan;65(1):78-84.

[17] Zwiers C, van Kamp I, Oepkes D, Lopriore E. Intrauterine transfusion and non-invasive treatment options for hemolytic disease of the fetus and newborn–review on current management and outcome. Expert review of hematology. 2017 Apr 3;10(4):337-44.

[18] Moise, Jr, K. Direct Fetal Transfusion. Glob. libr. women's med., (ISSN: 1756-2228) 2011;DOI10.3843 /GLOWM.10213

[19] American College of Obstetricians and Gynecologists, Committee on Obstetric Practice, Society for Maternal-Fetal Medicine. Medically indicated late-preterm and early-term deliveries: ACOG Committee Opinion, Number 831. Obstetrics and gynecology. 2021 Jul 1;138(1):e35-9.